BETHESDA, Md-An addendum to the National Toxicology Program’s Ninth Report on Carcinogens moves the dioxin TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) from the "reasonably anticipated" to cause human cancers category to the "known to be a human carcinogen" designation. A legal challenge to the change prevented the new designation from being published in the full report last May.
BETHESDA, MdAn addendum to the National Toxicology Program’s Ninth Report on Carcinogens moves the dioxin TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) from the "reasonably anticipated" to cause human cancers category to the "known to be a human carcinogen" designation. A legal challenge to the change prevented the new designation from being published in the full report last May.
TCDD is present as a contaminant in some herbicides and pesticides, and it is formed as an inadvertent byproduct in the incineration of waste.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.